Total Voting Rights

RNS Number : 4683H

C4X Discovery Holdings PLC

03 August 2021

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Total Voting Rights

3 August 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that pursuant to its block admission facility, details of which were announced on 1 July 2021, it has recently issued 1,100,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") in satisfaction of the exercise of warrants. The new Ordinary Shares rank pari passu with the Company's existing shares.

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, as of 3 August 2021, the Company has 227,812,697 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 227,812,697.

The above figure of 227,812,697 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery .

 

END

 

 

TVRDKNBDABKDNFK